Development

New open access journal highlights methods and clinical trial results

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials. The journal is a spin-off of the well-established title Contemporary Clinical Trials.

There are many ways to carry out a clinical trial. Researchers need to think about the number of patients to enroll, the type of treatments to give and their frequency, among many other factors. Contemporary Clinical Trials Communications publishes methodology and statistics that answer these questions, helping researchers build on each other's work and design better trials.

For example, in the first issue of the journal, which is now available on ScienceDirect, researchers from Genentech Inc. and the Deerfield Institute describe a new trial design that helps researchers take into account delayed effects of immune-oncology treatments.

"I trust that the readers will find the journal a valuable source of recent advancements in clinical trials," said Dr. Zhezhen Jin, co-Editor-in-Chief of Contemporary Clinical Trials Communications and Professor of Biostatistics at Columbia University in New York. He also explained that this knowledge can "facilitate the design, conduct and analysis of their trials."

The journal also aims to tackle the problem of publication bias towards positive results by making all trial data open access.

"A major objective of the journal is to reduce publication bias, which is a major issue in the field of clinical trials," said Dr. Zheng Su, co-Editor-in-Chief of Contemporary Clinical Trials Communications and VP at the Deerfield Institute in New York.

There are two main approaches to clinical trials: randomized and non-randomized. In randomized trials, the participants do not know whether they are receiving the treatment or a placebo. In non-randomized trials, the participants are often all given the treatment. Many clinical trials journals only publish randomized trials, but Contemporary Clinical Trials Communications will publish both.

"There are several existing clinical trials journals that either give preferential treatment to positive trial results due to their perceived higher significance, or focus only on randomized trials," added Dr. Jin. "In contrast, Contemporary Clinical Trials Communications provides a platform for trialists around the world to share their knowledge on all aspects of clinical trials. We're making scientifically valid and technically sound original research findings freely accessible regardless of their perceived importance or impact."

Contemporary Clinical Trials Communications is now open for submissions. The first issue is published on ScienceDirect.

About Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications is an international, peer-reviewed, open access journal that publishes articles on all aspects of clinical trials, including design, conduct, analysis, regulation and ethics. Articles appeal to a wide range of disciplines. Contemporary Clinical Trials Communications strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings, irrespective of their perceived importance, significance or impact.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

What's the secret to living a full …

If you have ever asked yourself, "What makes me feel most fulfilled?" you are not alone. Nearly 2 million people recently answered that question in a new survey by Abbott...

Read more

One family's history of the rare co…

In recognition of International Fabry Awareness month, Shire has released the trailer for Our Fabry Family Tree, a short film series featuring a family who were unknowing...

Read more

Bristol-Myers Squibb reports first …

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo, Eliquis and our hepatitis...

Read more

Researchers discover potential trea…

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that lead...

Read more

Bayer off to a successful start in …

The Bayer Group got off to a successful start in the new fiscal year. "All segments posted gains in their operating performance," said CEO Dr. Marijn Dekkers when he pres...

Read more

Ready. Raise. Rise. Campaign

The Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and le...

Read more

Pfizer reports first-quarter 2016 r…

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2016 and updated certain components of its 2016 financial guidance. Reported revenues totaled $13.0 b...

Read more

Research points to a new treatment …

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously ...

Read more

'Mediterranean' diet linked to lowe…

A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease...

Read more

Merck brings international start-up…

Merck, a leading science and technology company, has announced the participants for its Accelerator Programs in Darmstadt and Nairobi. Almost 200 highly competitive appli...

Read more

AstraZeneca completes acquisition o…

AstraZeneca has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015...

Read more

Why are women less likely to be pre…

Statins are equally effective at decreasing risk of coronary events in men and women, and yet women are less likely to be prescribed these cholesterol-lowering drugs than...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]